GWS
GILD icon

Greykasell Wealth Strategies’s Gilead Sciences GILD Stock Holding History

Greykasell Wealth Strategies’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
1,500
-351
-19% -$49.2K 0.08% 140
2025
Q4 		$227K Sell
1,851
-209
-10% -$25.4K 0.09% 139
2025
Q3 		$229K Buy
2,060
+532
+35% +$60.5K 0.1% 131
2025
Q2 		$169K Buy
+1,528
New +$163K 0.08% 137

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Greykasell Wealth Strategies's GILD Position: Q1 2026 in Review

Greykasell Wealth Strategies reduced its Gilead Sciences (GILD) stake by 19% in Q1 2026, selling an estimated $49.2K and leaving 1,500 shares worth $209K. The position accounts for 0.08% of the portfolio, ranked #140.

Greykasell Wealth Strategies first reported a position in GILD in Q2 2025 and has held it in 4 quarters since. The position peaked at $229K in Q3 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Greykasell Wealth Strategies held 1,500 shares of Gilead Sciences worth $209K as of Q1 2026.
  • Greykasell Wealth Strategies sold 351 Gilead Sciences shares in Q1 2026, an estimated $49.2K.
  • Gilead Sciences made up 0.08% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #140 holding.
  • Greykasell Wealth Strategies first reported a position in Gilead Sciences in Q2 2025 and has held it in 4 quarters since.
  • Greykasell Wealth Strategies's Gilead Sciences position peaked at $229K in Q3 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.